Literature DB >> 24633921

CARMA3 is upregulated in human pancreatic carcinoma, and its depletion inhibits tumor proliferation, migration, and invasion.

Shiyu Du1, Liping Jia, Yanli Zhang, Long Fang, Xiang Zhang, Yanhua Fan.   

Abstract

Elevated CARMA3 expression has been reported to be involved in tumor progression of several cancer types. In the present study, we examined the expression pattern of CARMA3 protein and its biological roles in human pancreatic carcinoma. Using immunohistochemistry, we checked CARMA3 protein expression in 95 pancreatic ductal carcinoma specimens. We found that CARMA3 was overexpressed in 34 of 95 (35.8 %) specimens. A significant association was observed between CARMA3 overexpression with histological grade (p=0.0099) and nodal status (p=0.0126). To further explore its biological roles, we knocked down CARMA3 expression in CAPAN2 cell line using small interfering RNA (siRNA). MTT growth assay, wound healing assay, and Transwell assay showed that CARMA3 depletion inhibited cell proliferation, migration, and invasion. We also showed that CARMA3 depletion inhibited EGF-induced nuclear factor-kappaB (NF-κB) activation and its target genes' expression. The effect of CARMA3 depletion on NF-κB signaling was significantly reduced in Bcl10-depleted cells. In conclusion, CARMA3 is overexpressed in pancreatic cancer and regulates malignant cell growth, invasion, and NF-κB signaling, which was dependent on its association with Bcl10.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24633921     DOI: 10.1007/s13277-014-1791-6

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  26 in total

Review 1.  NF-κB signaling pathways regulated by CARMA family of scaffold proteins.

Authors:  Marzenna Blonska; Xin Lin
Journal:  Cell Res       Date:  2010-12-28       Impact factor: 25.617

2.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

3.  CARMA3/Bcl10/MALT1-dependent NF-kappaB activation mediates angiotensin II-responsive inflammatory signaling in nonimmune cells.

Authors:  Linda M McAllister-Lucas; Jürgen Ruland; Katy Siu; Xiaohong Jin; Shufang Gu; David S L Kim; Peter Kuffa; Dawn Kohrt; Tak W Mak; Gabriel Nuñez; Peter C Lucas
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-13       Impact factor: 11.205

4.  Impact of tumor grade on prognosis in pancreatic cancer: should we include grade in AJCC staging?

Authors:  Nabil Wasif; Clifford Y Ko; James Farrell; Zev Wainberg; Oscar J Hines; Howard Reber; James S Tomlinson
Journal:  Ann Surg Oncol       Date:  2010-04-27       Impact factor: 5.344

Review 5.  Regulation of cyclin D1 gene expression.

Authors:  Ini-Isabée Witzel; Li Fang Koh; Neil D Perkins
Journal:  Biochem Soc Trans       Date:  2010-02       Impact factor: 5.407

6.  CARMA3 is overexpressed in colon cancer and regulates NF-κB activity and cyclin D1 expression.

Authors:  Zhifeng Miao; Tingting Zhao; Zhenning Wang; Yingying Xu; Yongxi Song; Jianhua Wu; Huimian Xu
Journal:  Biochem Biophys Res Commun       Date:  2012-08-02       Impact factor: 3.575

7.  CARMA3 overexpression accelerates cell proliferation and inhibits paclitaxel-induced apoptosis through NF-κB regulation in breast cancer cells.

Authors:  Tingting Zhao; Zhifeng Miao; Zhenning Wang; Yingying Xu; Jianhua Wu; Xingyu Liu; Yi You; Jiguang Li
Journal:  Tumour Biol       Date:  2013-05-25

8.  PKC-beta1 isoform activation is required for EGF-induced NF-kappaB inactivation and IkappaBalpha stabilization and protection of F-actin assembly and barrier function in enterocyte monolayers.

Authors:  A Banan; L J Zhang; A Farhadi; J Z Fields; M Shaikh; A Keshavarzian
Journal:  Am J Physiol Cell Physiol       Date:  2003-11-05       Impact factor: 4.249

9.  M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway.

Authors:  Chao-Ying Liu; Juan-Ying Xu; Xiao-Yan Shi; Wei Huang; Ting-Yan Ruan; Ping Xie; Jun-Li Ding
Journal:  Lab Invest       Date:  2013-06-10       Impact factor: 5.662

10.  Overexpression of CARMA3 in non-small-cell lung cancer is linked for tumor progression.

Authors:  Zixuan Li; Lianyue Qu; Qianze Dong; Bo Huang; Haiying Li; Zhongping Tang; Ying Xu; Wenting Luo; Lifeng Liu; Xueshan Qiu; Enhua Wang
Journal:  PLoS One       Date:  2012-05-15       Impact factor: 3.240

View more
  4 in total

1.  Rare variants in optic disc area gene CARD10 enriched in primary open-angle glaucoma.

Authors:  Tiger Zhou; Emmanuelle Souzeau; Shiwani Sharma; Owen M Siggs; Ivan Goldberg; Paul R Healey; Stuart Graham; Alex W Hewitt; David A Mackey; Robert J Casson; John Landers; Richard Mills; Jonathan Ellis; Paul Leo; Matthew A Brown; Stuart MacGregor; Kathryn P Burdon; Jamie E Craig
Journal:  Mol Genet Genomic Med       Date:  2016-10-03       Impact factor: 2.183

Review 2.  CARMA3 Is a Critical Mediator of G Protein-Coupled Receptor and Receptor Tyrosine Kinase-Driven Solid Tumor Pathogenesis.

Authors:  J Randall McAuley; Tanner J Freeman; Prasanna Ekambaram; Peter C Lucas; Linda M McAllister-Lucas
Journal:  Front Immunol       Date:  2018-08-15       Impact factor: 7.561

3.  CARD10 promotes the progression of renal cell carcinoma by regulating the NF‑κB signaling pathway.

Authors:  Longfei Peng; Ke He; Zhangjun Cao; Liangkuan Bi; Dexin Yu; Qi Wang; Jinyou Wang
Journal:  Mol Med Rep       Date:  2019-11-21       Impact factor: 2.952

4.  CARD10 cleavage by MALT1 restricts lung carcinoma growth in vivo.

Authors:  Laura Israël; Anton Glück; Marjorie Berger; Marine Coral; Melanie Ceci; Adeline Unterreiner; Joëlle Rubert; Maureen Bardet; Stefanie Ginster; Alexandra M Golding-Ochsenbein; Kea Martin; Thomas Hoyler; Thomas Calzascia; Grazyna Wieczorek; Rainer Hillenbrand; Stéphane Ferretti; Enrico Ferrero; Frédéric Bornancin
Journal:  Oncogenesis       Date:  2021-04-06       Impact factor: 7.485

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.